NCT06712927View on ClinicalTrials.gov

Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 6, 2025

Primary Completion Date

November 30, 2026

Study Completion Date

February 28, 2030

Conditions
MelanomaBrain Metastases
Interventions
DRUG

Ipilimumab

1 mg/kg of Ipilimumab will be administered via IV every 8 weeks. Participants will be assigned to Cohort A or B as per eligibility criteria. No randomization or blinding will occur

DRUG

Nivolumab + Relatlimab FDC

Relatlimab 160mg + Nivo 480mg will be administered via IV every 4 weeks. Participants will be assigned to Cohort A or B as per eligibility criteria. No randomization or blinding will occur

Trial Locations (1)

94304

RECRUITING

Stanford University, Palo Alto

All Listed Sponsors
lead

Stanford University

OTHER